Previous editions
Muy Global | Ed. 19 | Feb 2024
• ISO 9001:2015: We obtained certification.
• Cervical cancer: Prevention is key to protect yourself.
• Topical gene therapy for rare diseases: Krystal presents great success.
• Insulin shortage in the country: Minsalud clarifies situation.
• Dolutegravir: Requirements for its sale.
Muy Global | Ed. 18 | Feb 2024
• Blood test detected early stage Alzheimer's: New detection method.
• First subcutaneous injection of immunotherapy against cancer: European Commission approves Roche's Tecentriq SC.
• Studies to the Colombian health system: Recommendations of ANIF and AFIDRO.
• Risankizumab: lasting efficacy in psoriasis
• Top 10 most anticipated launches: New drugs for 2024.
Muy Global | Ed. 17 | Ene 2024
• Health benefit plan 2024 new drugs: procedures and increase in the UPC
• Cardiac pharmacotherapy: redefining pancreatic cancer treatment
• MSD acquires harpoon: Oncology Strategy
• Risankizumab: lasting efficacy in psoriasis
• Berdazimer: Advancement in the treatment of molluscum contagiosum
Subscribe
Keep informed of the most important news of the pharmaceutical industry